...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats.
【24h】

Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats.

机译：地塞米松，消炎痛和罗非昔布在胎鼠中增加了动脉导管的收缩。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: To find a better treatment for patent ductus arteriosus (PDA) in premature infants, the present study investigated the synergism of clinical doses of dexamethasone, indomethacin, and rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on the fetal ductus arteriosus (DA) in rats. METHODS AND RESULTS: Dexamethasone (0.3 mg/kg), indomethacin (0.3 mg/kg), and rofecoxib (0.3 mg/kg), alone or in combination, were administered to preterm (d19) and near-term (d21) fetal rats. The ratio of the inner diameter of the DA to that of the main pulmonary artery (PA) (DA/PA) was studied at 2, 4 and 8 h after drug administration, using a rapid whole-body freezing method. In near-term rats, the combined administration of dexamethasone and indomethacin caused severe constriction, with a DA/PA ratio of 0.52+/-0.08 at 8 h, whereas the DA/PA ratios were 0.83+/-0.03 and 0.90+/-0.02 with dexamethasone and indomethacin, respectively. Combined administration of dexamethasone and rofecoxib also caused severe constriction, with a DA/PA ratio of 0.64+/-0.07 at 8 h, compared with the DA/PA ratio of 0.92+/-0.03 with rofecoxib alone. CONCLUSIONS: Combined therapy may be an option in the medical management of PDA in premature infants before considering surgical treatment.
机译：背景：为了找到一种针对早产儿动脉导管未闭（PDA）的更好治疗方法，本研究调查了地塞米松，消炎痛和罗非考昔（一种选择性的环氧合酶-2（COX-2）抑制剂）的临床剂量对胎儿的协同作用。大鼠动脉导管（DA）。方法和结果：对早产（d19）和近期（d21）胎鼠分别或联合使用地塞米松（0.3 mg / kg），消炎痛（0.3 mg / kg）和罗非考昔（0.3 mg / kg）。 。使用快速全身冷冻方法，在给药后2、4和8小时研究了DA的内径与主要的肺动脉（PA）的内径之比（DA / PA）。在短期大鼠中，地塞米松和消炎痛的联合给药引起严重的收缩，在8 h时DA / PA比为0.52 +/- 0.08，而DA / PA比为0.83 +/- 0.03和0.90 +/-地塞米松和消炎痛分别为0.02。地塞米松和罗非考昔的联合给药也引起严重的收缩，在8 h时DA / PA比为0.64 +/- 0.07，而单独使用罗非考昔的DA / PA比为0.92 +/- 0.03。结论：在考虑手术治疗之前，联合治疗可能是早产儿PDA医疗管理中的一种选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号